C. Hernandez et al., Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients, THROMB RES, 99(2), 2000, pp. 119-127
It has been demonstrated in vitro that lipoprotein(a) [Lp(a)] increases the
endothelial synthesis of plasminogen activator inhibitor 1 (PAI-1). Howeve
r, this effect in vivo is controversial, and the possible relationship betw
een PAI-1 and Lp(a) phenotypes has not been evaluated. The aim of the study
was to determine the influence of Lp(a) and its phenotypes on PAI-1 serum
concentrations in diabetic patients. For this purpose we include 75 Caucasi
an diabetic patients (34 consecutive type I and 41 consecutive type II) wit
hout late diabetic complications. Lp(a) and PAI-1 were assessed by ELISA. L
p(a) phenotypes were determined by SDS-PAGE followed by immunoblotting, and
grouped according to size in small (F,B,S1,S2), big (S3,S4), and null. A l
inear correlation between Lp(a) and PAI-1 was not observed either as a whol
e or when type I and type II diabetic patients were analyzed separately. Ho
wever, significant differences were detected in PAI-I levels when Lp(a) phe
notypes were considered (small: 42.1+/-31.8 ng/mL; big: 37.2+/-26.1 ng/mL;
null: 14.4+/-14.4; p<0.05), The significant differences were due to the low
PAI-1 concentrations observed in patients with null phenotype. Our results
suggest that fibrinolytic activity might be preserved in diabetic patients
with null Lp(a) phenotype. Furthermore, it could be speculated that diabet
ic patients with null phenotype should be considered at low risk to develop
cardiovascular disease. (C) 2000 Elsevier Science Ltd. All rights reserved
.